RRM1 Expression As a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine Plus Cisplatin

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Oct 23

PMID 34682775

Citations 1

Authors

Jung Won Chun

Boyoung Lee

Weon Seo Park

Nayoung Han

Eun Kyung Hong

Eun Young Park

Sung Sik Han

Sang-Jae Park

Tae Hyun Kim

Woo Jin Lee

Sang Myung Woo

Affiliations

Soon will be listed here.

Abstract

The combination of gemcitabine plus cisplatin (GP) is regarded as a first-line treatment for patients with unresectable or recurrent biliary tract cancer (BTC). Several proteins including human equilibrative nucleoside transporter-1 (hENT1), deoxycytidine kinase (DCK), cytidine deaminase (CDA), and ribonucleotide reductase subunit 1 (RRM1) are known to be involved in gemcitabine uptake and metabolism. This study was aimed to identify the predictive and prognostic values of these biomarkers in patients who treated with GP for advanced BTC. Tumor samples were obtained from 34 patients with unresectable or recurrent BTC who were treated with GP between August 2015 and February 2018. Intratumoral expression of hENT1, DCK, CDA and RRM1 was determined by immunohistochemistry and analyzed for association with chemotherapy response, progression-free survival (PFS) and overall survival (OS). Median OS was significantly longer in the RRM1-negative group than in the RRM1-positive (9.9 months vs. 5.9 months, = 0.037). Multivariate adjustment analyses also demonstrated RRM1 expression as an independent prognostic factor for OS in patients treated with GP chemotherapy. Increased intratumoral expression of RRM1 on immunohistochemical staining may be a biomarker predicting poor survival in patients with GP chemotherapy for advanced BTC. Large-scale well-predefined prospective research is needed to validate the utility of biomarkers in clinical practice.

Citing Articles

The Roles of AGTRAP, ALKBH3, DIVERSIN, NEDD8 and RRM1 in Glioblastoma Pathophysiology and Prognosis.

Dumitru C, Walter N, Siebert C, Schafer F, Rashidi A, Neyazi B Biomedicines. 2024; 12(4).

PMID: 38672281 PMC: 11048029. DOI: 10.3390/biomedicines12040926.

References

Belkouz A, Labeur T, Dierks J, Dijk F, van Oijen M, Verheij J . Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2019; 141:82-94. DOI: 10.1016/j.critrevonc.2019.06.001. View

Tariq N, McNamara M, Valle J . Biliary tract cancers: current knowledge, clinical candidates and future challenges. Cancer Manag Res. 2019; 11:2623-2642. PMC: 6446989. DOI: 10.2147/CMAR.S157092. View

Borbath I, Verbrugghe L, Lai R, Gigot J, Humblet Y, Piessevaux H . Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. Eur J Cancer. 2011; 48(7):990-6. DOI: 10.1016/j.ejca.2011.11.006. View

Lane J, Martin T, McGuigan C, Mason M, Jiang W . The differential expression of hCNT1 and hENT1 i n breast cancer and the possible impact on breast cancer therapy. J Exp Ther Oncol. 2010; 8(3):203-10. View

Nakamura J, Kohya N, Kai K, Ohtaka K, Hashiguchi K, Hiraki M . Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma. Int J Oncol. 2010; 37(4):845-52. View

Amrutkar M, Gladhaug I . Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers (Basel). 2017; 9(11). PMC: 5704175. DOI: 10.3390/cancers9110157. View

Deng T, Pan H, Han R, Huang D, Li H, Zhou L . Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer. Int J Clin Exp Med. 2015; 7(12):5041-9. PMC: 4307450. View

Tibaldi C, Camerini A, Tiseo M, Mazzoni F, Barbieri F, Vittimberga I . Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study. Br J Cancer. 2018; 119(11):1326-1331. PMC: 6265283. DOI: 10.1038/s41416-018-0307-3. View

Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A . RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol. 2006; 24(29):4731-7. DOI: 10.1200/JCO.2006.06.1101. View

10.

Wakai T, Shirai Y, Sakata J, Takamura M, Matsuda Y, Korita P . Ribonucleotide reductase M1 expression in intrahepatic cholangiocarcinoma. Hepatogastroenterology. 2011; 58(110-111):1659-63. DOI: 10.5754/hge11175. View

11.

Voutsadakis I . Molecular predictors of gemcitabine response in pancreatic cancer. World J Gastrointest Oncol. 2011; 3(11):153-64. PMC: 3220724. DOI: 10.4251/wjgo.v3.i11.153. View

12.

Valle J, Wasan H, Palmer D, Cunningham D, Anthoney A, Maraveyas A . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14):1273-81. DOI: 10.1056/NEJMoa0908721. View

13.

Woo S, Yoon K, Hong E, Park W, Han S, Park S . DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study. Oncotarget. 2017; 8(46):81394-81404. PMC: 5655294. DOI: 10.18632/oncotarget.19037. View

14.

Macias R, Kornek M, Rodrigues P, Paiva N, Castro R, Urban S . Diagnostic and prognostic biomarkers in cholangiocarcinoma. Liver Int. 2019; 39 Suppl 1:108-122. DOI: 10.1111/liv.14090. View

15.

Park J, Oh D, Hsu C, Chen J, Chen L, Orlando M . Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Res Treat. 2015; 47(3):343-61. PMC: 4509359. DOI: 10.4143/crt.2014.308. View

16.

Gong W, Zhang X, Wu J, Chen L, Li L, Sun J . RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer. 2011; 75(3):374-80. DOI: 10.1016/j.lungcan.2011.08.003. View

17.

Sasaki H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N . Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. Br J Cancer. 2014; 111(7):1275-84. PMC: 4183840. DOI: 10.1038/bjc.2014.399. View

18.

Shuster J . Median follow-up in clinical trials. J Clin Oncol. 1991; 9(1):191-2. DOI: 10.1200/JCO.1991.9.1.191. View

19.

Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R . Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci. 2004; 95(9):753-7. PMC: 11158492. DOI: 10.1111/j.1349-7006.2004.tb03257.x. View

20.

Andre T, Reyes-Vidal J, Fartoux L, Ross P, Leslie M, Rosmorduc O . Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer. 2009; 99(6):862-7. PMC: 2538748. DOI: 10.1038/sj.bjc.6604628. View